Valuation: InspireMD, Inc.

Market Cap 22.31M 19.93M 18.59M 16.89M 31.78M 2.16B 32.09M 223M 87.3M 1.1B 83.78M 81.96M 3.53B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 22.31M 19.93M 18.59M 16.89M 31.78M 2.16B 32.09M 223M 87.3M 1.1B 83.78M 81.96M 3.53B EV / Sales 2026 *
2.28x
EV / Sales 2027 * 1.11x
Free-Float
80.03%
Yield 2026 *
-
Yield 2027 * -
1 day-6.61%
1 week-22.53%
Current month-28.12%
1 month-42.18%
3 months-30.74%
6 months-64.96%
Current year-73.03%
1 week 0.46
Extreme 0.4604
0.65
1 month 0.46
Extreme 0.4604
0.82
Current year 0.46
Extreme 0.4604
1.98
1 year 0.46
Extreme 0.4604
2.54
3 years 0.46
Extreme 0.4604
3.85
5 years 0.46
Extreme 0.4604
4.65
10 years 0.46
Extreme 0.4604
115,237.62
Manager TitleAgeSince
Chief Executive Officer 62 2019-12-31
Director of Finance/CFO 58 2025-06-24
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 71 2017-06-01
Director/Board Member 68 2013-02-06
Director/Board Member 62 2019-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/18/26 Others

Director

-183,746 0.3952%
9/18/26
Osiris Investment Partners LLC
OthersCompany -262,500 0.5646%
9/18/26 Others

Director

-91,874 0.1976%
Change 5-day change 1-year change 3-year change Capi.($)
-6.61%-22.53%-80.29%-85.54% 22.31M
-0.24%+1.86%-26.65%+1.66% 170B
+2.62%+1.52%-10.34%+15.28% 112B
+0.57%+1.47%-26.20%+4.18% 106B
+2.06%+2.21%-47.50%-10.62% 73.6B
+1.29%+3.73%+3.46%+74.79% 61.32B
+0.12%+3.62%+12.66%+65.87% 52.89B
+1.44%+2.63%-5.76%-30.36% 49.78B
+1.28%-0.89%-18.54%+15.06% 40.43B
+0.13%-2.11%+24.54%+1.43% 31.85B
Average -0.28%-1.09%-17.46%+5.17% 69.88B
Weighted average by Cap. +0.36%+1.54%-16.25%+12.70%

Financials

2026 *2027 *
Net sales 9.8M 8.75M 8.16M 7.42M 13.95M 949M 14.09M 98.01M 38.33M 482M 36.79M 35.99M 1.55B 20.13M 17.98M 16.77M 15.23M 28.67M 1.95B 28.95M 201M 78.76M 991M 75.59M 73.95M 3.19B
Net income - -
Net Debt - -
Projected Income Statement - Annual - InspireMD, Inc.
Logo InspireMD, Inc.
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
Employees
127
Date Price Change Volume
26-10-08 US$0.4800 -6.61% 225,415
26-10-07 US$0.5140 -2.13% 145,454
26-10-06 US$0.5252 -9.46% 230,453
26-10-05 US$0.5801 -6.81% 136,210
26-10-02 US$0.6225 +0.47% 68,739
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.4800USD
Average target price
3.333USD
Spread / Average Target
+594.44%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - InspireMD, Inc.
  1. Stock Market
  2. Stocks
  3. NSPR Stock